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Abstract
Background: TAS-102, a new treatment option for patients with metastatic colorectal cancer that is refractory or
intolerant to standard therapies, has been improving survival with acceptable tolerability and adverse events.
Adverse hematological events associated with TAS-102 treatment were extensively profiled in the RECOURSE trial,
but pulmonary toxicities associated with TAS-102 therapy are distinctly uncommon. In a recent early post-marketing
phase vigilance on TAS-102 in Japan, seven cases of pulmonary disease were reported, but patient follow-up in
this study was incomplete. Here, we present the first case of interstitial lung disease occurring in association with
TAS-102 treatment.
Case presentation: A 57-year-old Japanese man who had previously received two standard treatments was
admitted in 2014, at which time we administered TAS-102 (110 mg/day) as a third-line chemotherapy. He was
safely treated with TAS-102 for the first planned cycle; however, approximately 4 days after receiving the second
cycle of TAS-102, he complained of high fever and subsequent dyspnea with severe hypoxemia and went to
the emergency room. A chest X-ray revealed diffuse coarse reticular shadows with ground-glass opacity on both
lungs. Furthermore, a chest computed tomography scan showed thickening of the bronchovascular bundles with
extensive ground-glass opacification and pleural effusions in both lung fields.
In addition, a peripheral blood lymphocyte stimulation test with TAS-102 showed higher values compared with
control samples. Consequently, we suspected drug-induced interstitial pneumonia, and discontinued treatment.
Our patient was given an initial administration of high-dose methylprednisolone (1000 mg/day) for 3 days and
oxygen. Our patient was discharged with oral prednisolone (20 mg/day) and improved symptomatically and
radiologically.
Conclusions: These findings suggest that interstitial pneumonia is a rare complication of TAS-102 chemotherapy,
but the possibility of interstitial pneumonia should always be considered when a patient presents with a respiratory
disorder while undergoing TAS-102 systemic chemotherapy.
Prompt discontinuation of TAS-102 and treatment with high-dosage corticosteroids is needed to avoid
exacerbating respiratory symptoms.
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Background
TAS-102 was first approved in Japan in March 2014 for
the treatment of metastatic colorectal cancer (mCRC)
and has demonstrated efficacy in fluorouracil (5-Fu) re-
fractory patients based on having a different mechanism
of action [1]. The safety of TAS-102 with the Japanese
recommended dose has also been independently con-
firmed [2]. The toxicity profile of TAS-102 differs from
the known adverse effects of 5-Fu and its derivatives. In
the RECOURSE trial, TAS-102 was associated with a
favorable overall safety profile, but treatment was
accompanied with a significant increase of hematological
toxicities. In particular, 38 % of patients presented with
grade 3–4 neutropenia, although febrile neutropenia was
only observed in 4 % of the patients [3]. However, TAS-
102 has never been clearly associated with incidences of
interstitial pneumonia (IP). According to the phase 2
trial (J003 trial) involving 169 Japanese patients, there
was one suspected case of interstitial lung disease (ILD)
[4]. A few reports of IP were reported for TAS-102 in
combined therapy with fluorouracil, leucovorin, and oxa-
liplatin (FOLFOX4) [0.6 % (2 out of 322 patients)] and
with fluorouracil, leucovorin, and irinotecan (FOLFIRI)
[0.7 % (2 out of 302 patients)] [5]. Induced ILD has also
been reported in 1.3 % (39 out of 3085) of patients
receiving the molecularly targeted therapy panitumu-
mab [6]. There have been no reports of ILD in pa-
tients receiving TAS-102 chemotherapy, whereas
seven cases were reported from the early post-
marketing phase vigilance (EPPV) on TAS-102 in
Japan [7]. Herein, to the best of our knowledge, we
report the first case of IP associated with TAS-102
therapy in a patient with mCRC.
Case presentation
The patient was a 57-year-old Japanese man with rectal
adenocarcinoma. The tumor was located in the middle
rectum and had invaded the serosa with regional metas-
tases. His past medical history was hypertension, hepa-
titis C virus infection, subarachnoid hemorrhage, and
chronic obstructive pulmonary disease. His social history
was significant, including a 20 pack-year smoking his-
tory. A low anterior resection was performed in 2010;
pathology revealed a stage IIIB moderately differentiated,
KRAS wild-type adenocarcinoma, with one out of 15
lymph nodes testing positive. After surgery, he received
12 cycles of adjuvant FOLFOX chemotherapy. One year
later, a subsequent positron emission tomography/com-
puted tomography (PET/CT) scan showed evidence of
recurrence, with liver, lung and pelvic lymph node me-
tastases. Additionally, his carcinoembryonic antigen
(CEA) values had increased to 23 ng/ml. He subse-
quently received 15 cycles of FOLFIRI + cetuximab ther-
apy followed by 12 cycles of FOLFOX + bevacizumab;
however, a PET/CT scan in June 2014 revealed progres-
sive disease.
TAS-102 was subsequently considered as a third-line
chemotherapy option, and he began 110 mg daily TAS-
102 treatment in June 2014. He had no history of food
or medication allergy. He was safely treated with TAS-
102 for the first planned cycle; however, approximately 4
days after receiving the second cycle of TAS-102, he
complained of high fever and subsequent dyspnea with
severe hypoxemia and went to the emergency room. On
examination, his respiratory rate was 33 breaths per
minute and fine crackles were heard by chest asuculata-
tion. Laboratory values upon admission were: white
blood cell (WBC) count 4100/μL (neutrophils 52.0 %,
eosinophils 1.0 %), C-reactive protein (CRP) 6.13 mg/dL
(normally under 0.10 mg/mL), lactate dehydrogenase
(LDH) 482 IU/mL (normally 114–220 IU/mL), alkaline
phosphatase 415 IU/mL (normally 124–367 IU/mL), and
KL-6 562 U/mL (normally 105–401 U/mL). Blood gas
under oxygen supplementation (10 L/min) revealed a
pH of 7.51, pO2 of 50.3 mmHg, pCO2 of 34.3 mmHg,
and HCO3- 27.9 mmol/L. All infectious workup tests
were performed, and the results were all negative includ-
ing common bacteria, fungi, Pneumocystis, Legionella
and Cytomegalovirus. A chest radiograph revealed a
ground-glass opacity and lower consolidation (Fig. 1).
Furthermore, a chest computed tomography (CT) scan
showed thickening of the bronchovascular bundles and
interlobular septum, diffuse areas of defined ground-
glass opacities with fine reticulation and pleural effu-
sions in both lung fields (Fig. 2). Of note, Fig. 2 shows a
Fig. 1 Chest X-ray obtained in June 2014 showing reticulonodular
shadows in both lung fields
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nodular lesion in the left middle lung field. The appear-
ance of the abnormalities in the CT scan was described
as lesions in the form of ground-glass opacities with vis-
ible polygonal structures, of the so-called crazy paving
pattern. It also revealed a metastatic nodular lesion in
the left middle lung field.
The rapid onset and nature of these changes were
consistent with drug-induced fibrotic lung disease sec-
ondary to TAS-102 chemotherapy. In addition, a per-
ipheral blood drug-induced lymphocyte stimulation
test (DLST) with TAS-102 showed that the value for
TAS-102 was higher than that of control [973 vs. 476
counts per minute (cpm)]. Thus, he commenced em-
pirical broad-spectrum antibiotics and high-dose
intravenous corticosteroid therapy (1000 mg/day for 3
days). Because of his severe dyspnea, bronchoscopy
and bronchoalveolar lavage were not performed.
Three days later, there was a marked improvement in
terms of symptoms and oxygen requirements. Intra-
venous antibiotics were stopped and oral prednisolone
commenced. A CT scan performed approximately 12
days after the prednisolone treatments began showed
improvements of the previously observed pulmonary
lesions (Fig. 3). Blood gas analysis revealed complete
recovery of pulmonary function. Our patient was dis-
charged home with oral prednisolone (20 mg/day).
Unfortunately, he died from mCRC disease progres-
sion approximately 1 year after the last administration
of TAS-102.
Discussion
Several major breakthroughs, including improvements
to standard chemotherapy regimens and molecularly tar-
geted agents, have been achieved in the treatment of
mCRC. These advances have increased the survival of
mCRC patients in the past 20 years from 12 months to
approximately 30 months [8, 9]. This has led to in-
creased numbers of heavily pretreated mCRC patients
presenting to daily clinical practices where clinicians
have few further treatments to offer. TAS-102 is a new
treatment option for patients who have failed all the
standard therapies. The reason for this is as follows;
TAS-102 is an oral combination drug consisting of tri-
fluridine, which is a thymidine-based nucleoside analog,
and tipiracil hydrochloride, which improves the bioavail-
ability of trifluridine by inhibiting its catabolism by thy-
midine phosphorylase [10]. In the RECOURSE trial,
TAS-102 significantly increased overall survival in com-
parison to placebo, reducing the risk of death more than
30 % in refractory, heavily pretreated mCRC patients. In
addition, TAS-102 was found to be a well-tolerated drug
in this trial. In the TAS-102 group, only one treatment-
related death due to septic shock occurred and only 4 %
of patients discontinued treatment because of any toxic
effects. In terms of toxicity, TAS-102 is associated with a
favorable overall safety profile, but treatment is accom-
panied by a significant increase of hematological toxicity,
in particular 38 % of patients experienced grade 3–4
neutropenia, although febrile neutropenia was observed
Fig. 2 Computed tomography scan showing features of interstitial lung disease
Fig. 3 Computed tomography scan approximately 12 days after discontinuing TAS-102 treatment showing improvement of
interstitial pneumonitis
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in only 4 % of patients. Furthermore, the frequency of
hematological toxicity was shown to peak during the
first cycle and gradually taper off with subsequent cycles.
Incidences of IP associated with TAS-102 have not
been reported. Using the key words “TAS-102,” “pneu-
monitis” and “interstitial” on PubMed identifies no re-
ports of lung toxicity in patients receiving TAS-102.
However, IP was noted in seven of 3373 patients from
1209 institutes according to an EPPV on TAS-102 in
Japan. Consequently, these EPPV data have noted that
the incidence rate of ILD for TAS-102 was comparable
to other standard cytotoxic agents. The previous report
of ILD in Japanese patients with lung cancer suggested
that increased age, poor performance status, reduced
normal lung area on CT scans, preexisting chronic ILD,
and concurrent cardiac disease were risk factors for ILD
[11]. Indeed, our patient had minor emphysematous
changes on chest CT upon his cancer diagnosis and a
history of heavy smoking. No other reported risk factors
for ILD were observed in our patient.
In general, approximately 15–50 % of ILD-related
deaths occurred in patients receiving other cytotoxic
drugs. Nonetheless, ILD-related deaths associated with
TAS-102 chemotherapy were not reported in the previous
EPPV. Our results will help clinicians improve ILD out-
comes based on prompt cessation of TAS-102 chemother-
apy and initiation of corticosteroids. Several types of
pulmonary complications associated with oxaliplatin-
based treatments have been reported in colorectal cancer
patients, including acute lung injury, eosinophilic lung dis-
ease, cryptogenic organizing pneumonia and IP or pul-
monary fibrosis [12–15]. The exact pathogenesis of TAS-
102-induced ILD is unknown. In our case, a positive reac-
tion for TAS-102 was observed upon DLST, and the result
suggested a type-1 or type-4 hypersensitivity reaction to-
wards TAS-102. Although new antineoplastic agents are
constantly being developed and there are many reports of
chemotherapy-induced IP, to the best of our knowledge,
this is the first documented case of TAS-102-induced IP.
Conclusions
In conclusion, we experienced a rare adverse event during
TAS-102 chemotherapy. Though TAS-102 is known for
its safety and efficacy in clinical practice, clinicians should
be especially aware of a possibility of IP associated with
TAS-102 therapy; moreover, early diagnosis, careful moni-
toring and timely management are needed in order to
prevent the associated morbidity and mortality.
Abbreviations
5-Fu: Fluorouracil; cpm: Count per minute; CEA: Carcinoembryonic antigen;
CRP: C-reactive protein; CT: Computed tomography; DLST: Drug-induced
lymphocyte stimulation test; EPPV: Early post-marketing phase vigilance;
ILD: Interstitial lung disease; IP: Interstitial pneumonia; LDH: Lactate
dehydrogenase; mCRC: Metastatic colorectal cancer; PET/CT: Positron
emission tomography/computed tomography; WBC: White blood cell
Funding
There are no financial interests.
Authors’ contributions
HK, NI, MT, KY, and YA analyzed the data from our patient regarding the
development of interstitial pneumonitis and participated in the treatment
of this patient. MU diagnosed the radical findings. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient’s next of kin for
publication of this case report and any accompanying images. A copy of the
written consent is available for review by the Editor-in-Chief of this journal.
Ethics approval and consent to participate
All procedures used in this study were approved by the Ethics Committee of
Kurume University School of Medicine.
Author details
1Department of Surgery, Kurume University School of Medicine, 67
Asahimachi, Kurume, Fukuoka 830-0011, Japan. 2Department of Radiology,
Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka
830-0011, Japan.
Received: 11 April 2016 Accepted: 11 October 2016
References
1. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review
of the mechanism of action. Cancer Treat Rev. 2015;41(9):777–83.
2. Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, et al. Phase I
study of TAS-102 treatment in Japanese patients with advanced solid
tumours. Br J Cancer. 2012;107(3):429–34.
3. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R,
Mizunumale N, RECOURSE Study Group, et al. Randomized trial of
TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;
372(20):1909–19.
4. Yoshino T, Mizunumale N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al.
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a
double-blind, randomised, placebo-controlled phase 2 trial. Lancet
Oncol. 2012;13(10):993–1001.
5. Boku N, Sugihara K, Kitagawa Y, Hatake K, Gemma A, Yamazaki N, et al.
Panitumumab in Japanese patients with unresectable colorectal cancer: a
post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol. 2014;
44(3):214–23.
6. Osawa M, Kudoh S, Sakai F, Endo M, Hamaguchi T, Ogino Y, et al. Clinical
features and risk factors of panitumumab-induced interstitial lung
disease: a postmarketing all-case surveillance study. Int J Clin Oncol.
2015;20(6):1063–71.
7. Muro K, Uetake H, Fujita N, Furuta T, Hara N, Katori J, et al. Initial safety
survey report from early post-marketing phase vigilance (EPPV) on TAS-102
for metastatic colorectal cancer (mCRC). Eur J Cancer. 2015;51:S367. abstract
2113.
8. Heinemalen V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab
as first-line treatment for patients with metastatic colorectal cancer(FIRE3):
a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.
9. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal
cancer. N Engl J Med. 2014;371(17):1609–18.
10. Salvatore L, Rossini D, Moretto R, Cremolini C, Schirripa Maletoniotti C, et al.
TAS-102 for the treatment of metastatic colorectal cancer. Expert Rev
Anticancer Ther. 2015;15(11):1283–92.
11. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al.
Interstitial lung disease in Japanese patients with lung cancer. Cancer: a
cohort and nested case-control study. Am J Respir Crit Care Med. 2008;
177(12):1348–57.
Kamei et al. Journal of Medical Case Reports  (2016) 10:310 Page 4 of 5
12. Ishizone S, Koide N, Akita N, Karasawa F, Kobayashi N, Koizumi T, et al. Fatal
interstitial pneumonia associated with oxaliplatin-based therapy in a patient
with metastatic rectal cancer. Clin J Gastroenterol. 2011;4(3):157–61.
13. Hannan LM, Yoong J, Chong G, McDonald CF. Interstitial lung disease in a
patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for
metastatic colorectal cancer. Radiol Oncol. 2012;46(4):360–2.
14. Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C, Ishihara T. Interstitial
lung disease during chemotherapy combined with oxaliplatin and/or
bevacizumab in advanced colorectal cancer patients. Jpn J Clin Oncol.
2011;41(4):498–502.
15. Soon WC, West K, Gibeon D, Bowen EF. Pulmonary fibrosis secondary to
FOLFOX chemotherapy: a case report. Case Rep Oncol. 2014;7(3):662–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kamei et al. Journal of Medical Case Reports  (2016) 10:310 Page 5 of 5
